Our objective is to determine if the combination of simple ultrasound features (IOTA simple rules) and a new biomarker (HE4) together with a common tumour marker (CA 125) can accurately predict ovarian cancer in women found to have a pelvic mass on ultrasound. The investigators hypothesize that the use of two biomarkers (HE4 and CA 125) in a mathematical algorithm (Risk of Malignancy Algorithm, ROMA) can be used to predict malignancy in a pelvic mass which has indeterminate ultrasound features. This is a prospective cohort study involving women undergoing operation for a pelvic mass. 720 women scheduled to have an operation to remove a pelvic mass would be recruited from 3 hospitals (QMH, UCH and PYNEH). Pre-operatively, each woman will have an ultrasound assessment using the IOTA simple rules criteria and have blood taken for tumour markers HE4 and CA 125. In women where IOTA ultrasound rules are inconclusive, 2 strategies for prediction will be compared - calculation of risk by ROMA (Strategy A) vs referral for an expert ultrasound (Strategy B). These pre-operative risk predictions will be correlated with the final pathology found at the operations.
Main outcome measures include the sensitivity, specificity, positive and negative predictive powers for Strategy A compared to Strategy B. Sensitivity and specificity will be compared using the McNemar test. Area Under the ROC Curve (AUC) will be calculated and compared using the Delong method for the 2 strategies.
The investigators expect AUC of both strategies will be similar. This would suggest that ROMA can replace expert ultrasound in the pre-operative prediction of ovarian cancer.
| Condition or disease |
|---|
| Pelvic Mass |
| Study Type : | Observational |
| Estimated Enrollment : | 720 participants |
| Observational Model: | Other |
| Time Perspective: | Prospective |
| Official Title: | The Use of a New Biomarker, HE4, in Combination With Simple Ultrasound Rules in the Prediction of Malignancy in a Pelvic Mass Detected on Ultrasound |
| Actual Study Start Date : | April 1, 2018 |
| Estimated Primary Completion Date : | April 10, 2020 |
| Estimated Study Completion Date : | September 30, 2020 |
| Ages Eligible for Study: | 18 Years and older (Adult, Older Adult) |
| Sexes Eligible for Study: | Female |
| Accepts Healthy Volunteers: | No |
| Sampling Method: | Non-Probability Sample |
Inclusion Criteria:
Exclusion Criteria:
| Contact: Karen Kar Loen Chan, MBBChir | +852 22554517 | kklchan@hku.hk |
| Hong Kong | |
| Pamela Youde Nethersole Eastern Hospital | Recruiting |
| Hong Kong, Hong Kong | |
| Contact: Carmen Ka Man Choi, MBBS +852 25956815 choikm@ha.org.hk | |
| Queen Mary Hospital | Recruiting |
| Hong Kong, Hong Kong | |
| Contact: Karen Kar Loen Chan, MBBChir +852 22554517 kklchan@hku.hk | |
| Sub-Investigator: Hextan Yuen Sheung Ngan, MBBS, MD | |
| Principal Investigator: Karen Kar Loen Chan, MBBChir | |
| Sub-Investigator: Vincent Yuk Tong Cheung, MBBS | |
| Sub-Investigator: Ka Yu Tse, MBBS, MMedsc | |
| Sub-Investigator: Mandy Man Yee Chu, MBBS | |
| Sub-Investigator: Michelle Kwan Yee Siu, Bsc, PhD | |
| United Christian Hospital | Recruiting |
| Hong Kong, Hong Kong | |
| Contact: Victoria Yu Ka Chai, MBBS +852 39494385 cyk095a@ha.org.hk | |
| Tracking Information | |||||
|---|---|---|---|---|---|
| First Submitted Date | January 29, 2019 | ||||
| First Posted Date | June 12, 2019 | ||||
| Last Update Posted Date | June 12, 2019 | ||||
| Actual Study Start Date | April 1, 2018 | ||||
| Estimated Primary Completion Date | April 10, 2020 (Final data collection date for primary outcome measure) | ||||
| Current Primary Outcome Measures |
sensitivity, specificity and predictive powers [ Time Frame: 3 months after last subject enrolled ] The group of women with inconclusive IOTA assessment will undergo further assessment by both tumour markers assessment by ROMA (Strategy A) and expert ultrasound (Strategy B). The prediction of risk of malignancy (high or low) will be correlated with the final histopathology result from the surgery. The sensitivity, specificity and predictive powers for the 2 strategies will be compared.
|
||||
| Original Primary Outcome Measures | Same as current | ||||
| Change History | No Changes Posted | ||||
| Current Secondary Outcome Measures |
|
||||
| Original Secondary Outcome Measures | Same as current | ||||
| Current Other Pre-specified Outcome Measures | Not Provided | ||||
| Original Other Pre-specified Outcome Measures | Not Provided | ||||
| Descriptive Information | |||||
| Brief Title | The Use of HE4 With Simple Ultrasound Rules to Predict Malignancy in a Pelvic Mass | ||||
| Official Title | The Use of a New Biomarker, HE4, in Combination With Simple Ultrasound Rules in the Prediction of Malignancy in a Pelvic Mass Detected on Ultrasound | ||||
| Brief Summary |
Our objective is to determine if the combination of simple ultrasound features (IOTA simple rules) and a new biomarker (HE4) together with a common tumour marker (CA 125) can accurately predict ovarian cancer in women found to have a pelvic mass on ultrasound. The investigators hypothesize that the use of two biomarkers (HE4 and CA 125) in a mathematical algorithm (Risk of Malignancy Algorithm, ROMA) can be used to predict malignancy in a pelvic mass which has indeterminate ultrasound features. This is a prospective cohort study involving women undergoing operation for a pelvic mass. 720 women scheduled to have an operation to remove a pelvic mass would be recruited from 3 hospitals (QMH, UCH and PYNEH). Pre-operatively, each woman will have an ultrasound assessment using the IOTA simple rules criteria and have blood taken for tumour markers HE4 and CA 125. In women where IOTA ultrasound rules are inconclusive, 2 strategies for prediction will be compared - calculation of risk by ROMA (Strategy A) vs referral for an expert ultrasound (Strategy B). These pre-operative risk predictions will be correlated with the final pathology found at the operations. Main outcome measures include the sensitivity, specificity, positive and negative predictive powers for Strategy A compared to Strategy B. Sensitivity and specificity will be compared using the McNemar test. Area Under the ROC Curve (AUC) will be calculated and compared using the Delong method for the 2 strategies. The investigators expect AUC of both strategies will be similar. This would suggest that ROMA can replace expert ultrasound in the pre-operative prediction of ovarian cancer. |
||||
| Detailed Description | Not Provided | ||||
| Study Type | Observational | ||||
| Study Design | Observational Model: Other Time Perspective: Prospective |
||||
| Target Follow-Up Duration | Not Provided | ||||
| Biospecimen | Not Provided | ||||
| Sampling Method | Non-Probability Sample | ||||
| Study Population | Women found to have a pelvic mass on ultrasound in Hong Kong | ||||
| Condition | Pelvic Mass | ||||
| Intervention | Not Provided | ||||
| Study Groups/Cohorts | Not Provided | ||||
| Publications * | Not Provided | ||||
|
* Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline. |
|||||
| Recruitment Information | |||||
| Recruitment Status | Unknown status | ||||
| Estimated Enrollment |
720 | ||||
| Original Estimated Enrollment | Same as current | ||||
| Estimated Study Completion Date | September 30, 2020 | ||||
| Estimated Primary Completion Date | April 10, 2020 (Final data collection date for primary outcome measure) | ||||
| Eligibility Criteria |
Inclusion Criteria:
Exclusion Criteria:
|
||||
| Sex/Gender |
|
||||
| Ages | 18 Years and older (Adult, Older Adult) | ||||
| Accepts Healthy Volunteers | No | ||||
| Contacts | Contact information is only displayed when the study is recruiting subjects | ||||
| Listed Location Countries | Hong Kong | ||||
| Removed Location Countries | |||||
| Administrative Information | |||||
| NCT Number | NCT03982914 | ||||
| Other Study ID Numbers | UW 17-551 | ||||
| Has Data Monitoring Committee | No | ||||
| U.S. FDA-regulated Product |
|
||||
| IPD Sharing Statement | Not Provided | ||||
| Responsible Party | The University of Hong Kong | ||||
| Study Sponsor | The University of Hong Kong | ||||
| Collaborators |
|
||||
| Investigators | Not Provided | ||||
| PRS Account | The University of Hong Kong | ||||
| Verification Date | June 2019 | ||||